- Home
- HAFN vs DNLI Comparison
HAFN vs DNLI Comparison
Compare HAFN & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HAFN | DNLI |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 2020 | 2017 |
Fundamental Metrics
Financial Performance| Metric | HAFN | DNLI |
|---|---|---|
| Price | $9.38 | $21.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $34.33 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.21% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $408.85 |
| P/E Ratio | $11.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.17 | $12.58 |
| 52 Week High | $9.54 | $27.30 |
Technical Indicators
Market Signals| Indicator | HAFN | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 73.24 | 30.08 |
| Support Level | $7.84 | $17.99 |
| Resistance Level | $9.54 | $22.07 |
| Average True Range (ATR) | 0.26 | 0.74 |
| MACD | 0.10 | -0.35 |
| Stochastic Oscillator | 99.55 | 5.49 |
Price Performance
Historical ComparisonAbout HAFN Hafnia Limited
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk. Company manages it's business through the following reporting segments: LR2 tankers, LR1 tankers, MR tankers, Handy tankers.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.